Bárbara I. Rojo-Rodríguez, Departamento Clínico de Medicina Interna, Unidad Médica de Alta Especialidad Nº 1, Centro Médico Nacional Bajío, IMSS, León, Gto., México
Alejandro Olmos-Guzmán, Departamento Clínico de Radioterapia, Unidad Médica de Alta Especialidad Nº 1, Centro Médico Nacional Bajío, IMSS, León, Gto., México
Plácido D. Esqueda-Guerrero, Departamento Clínico de Radioterapia, Unidad Médica de Alta Especialidad Nº 1, Centro Médico Nacional Bajío, IMSS, León, Gto., México
Miguel A. Souto-del Bosque, Departamento Clínico de Radioterapia, Unidad Médica de Alta Especialidad Nº 25, Centro Médico Nacional Noreste, IMSS, Monterrey, N.L., México
Rafael Luna-Montalbán, Departamento Clínico de Infectología, Unidad Médica de Alta Especialidad Nº 1, Centro Médico Nacional Bajío, IMSS, León, Gto., México
Yennira A. Carrasco-Ángeles, Departamento Clínico de Radioterapia, Unidad Médica de Alta Especialidad Nº 1, Centro Médico Nacional Bajío, IMSS, León, Gto., México
Flavio M. Calva-Barrera, Departamento Clínico de Radioterapia, Unidad Médica de Alta Especialidad Nº 1, Centro Médico Nacional Bajío, IMSS, León, Gto., México
Cindy S. Ortiz-Arce, Unidad Médica de Alta Especialidad Nº 25, División de Investigación en Salud, Centro Médico Nacional Noreste, IMSS, Monterrey, N.L. México
Background: Hypofractionated schedules of radiotherapy in breast cancer offered similar outcomes and toxicities than conventional treatment. Skin is the first damage site, with radiodermatitis in mainly cases, however, there is not a clear indication for cutaneous prophylaxis. Objective: To determine the benefit of a cutaneous prophylactic intervention for hypofractionated breast cancer radiotherapy. Method: A prospective, experimental, double-blind, pilot, randomized, controlled study. We included patients with breast cancer diagnosis treated with conservative surgery and hypofractionated radiotherapy with a dose of 40 Gy in 15 sessions; they were randomly assigned to prophylaxis with hyaluronic acid or aloe vera; historic control group without prophylaxis were used. A χ2 test was performed to compare results between groups. Results: Twenty-nine patients were included, 12 treated with hyaluronic acid, 8 with aloe vera and 9 without prophylactic management. There is a significant improvement in radiodermatitis grade during and until eight weeks after radiotherapy. Without a difference between prophylactic products. Conclusions: Cutaneous prophylactic in patients treated with hypofractionated radiotherapy for breast cancer improve the severity of radiodermatitis without difference in the prophylactic product.
Keywords: Radiodermatitis. Breast neoplasms. Radiotherapy. Radiation dose hypofractionation. Prevention and control.
